New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial

Table 4 Treatment-related adverse events during the study n (%)

System organ class preferred term	High dose (n = 23)	Low dose (n = 26)	Placebo (n = 24)
Gastrointestinal disorders
Abdominal pain upper	0	1 (3.85)	0 (0)
Nausea	0	0 (0)	1 (4.17)
Nervous system disorders
Dizziness	0	1 (3.85)	0 (0)